Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Oct 8;8(19):5190-5191.
doi: 10.1182/bloodadvances.2024013924.

Bridging radiotherapy before CAR-T therapy in CNS lymphoma

Ulrike Bacher  1 , Thomas Pabst  2
Affiliations
Comment

Bridging radiotherapy before CAR-T therapy in CNS lymphoma

Ulrike Bacher et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Comment on

References

    1. Cederquist G, Schefflein J, Devlin S, et al. CNS bridging radiotherapy achieves rapid cytoreduction prior to CAR T cell therapy for aggressive B-cell lymphoma. Blood Adv. 2024;8(19):5192–5199. - PubMed
    1. Elgohary G, Yang Y, Gergis M, Yi D, Gergis U. Chimeric antigen receptor T - cell therapy for large B-cell lymphoma patients with central nervous system involvement, a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2024;24(4):e142–e151. - PubMed
    1. Shumilov E, Boyadzhiev H, Mazzeo P, et al. CAR-T cell therapy shows similar efficacy and toxicity in patients with DLBCL regardless of CNS involvement. Hemasphere. 2023;7(12):e984. - PMC - PubMed
    1. Ryan C, Zon R, Redd R, et al. Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement. Br J Haematol. 2023;203(5):774–780. - PMC - PubMed
    1. Kline K, Luetkens T, Koka R, et al. Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells. Cancer Immunol Immunother. 2024;73(3):45. - PMC - PubMed

MeSH terms

Substances